171,310 research outputs found
Radiotherapy combined with simultaneous chemotherapy with mitomycin-C and 5-fluorouracil for inoperable head and neck cancer
No full textThe feasibility and effectiveness of a combined chemoradiotherapy treatment modality for locally advanced head and neck cancer was tested in a phase II trial. From March 1995 to June 1998, 35 patients with advanced squamous cell carcinoma of the head and neck were treated with a continuous intravenous infusion of 5-fluorouracil (600 mg m(-2) 24 h(-1) for Days 1 to 5 (120 h)) and mitomycin-C (10 mg m(-2) intravenously) on Day 5 during the first week of radiotherapy and on Day 36. 31 patients had stage IV disease; 4 patients had stage Ill. and 1 patient had stage II. Patient ages ranged from 42-69 years (median 56.7 years). The tumours involved were as follows: oral cavity (n=11); oropharynx (n=14); hypopharynx/larynx (n=10). Radiotherapy was delivered to a total dose of 70 Gy with conventional fractionation (1 Gy per fraction, five times a week). Chemotherapy was well tolerated and all patients received the intended dose. Mild nausea occurred in five patients. After a mean follow-up of 21 months (range 10-44 months), 8 (23%) patients remain alive. A complete response was seen in 28 (80%) patients. When a recurrence appeared, it was within the first year after treatment. 1- and 2-year overall survival rates were 46% and 23%, respectively. Grade 3 mucositis occurred in 17% of patients. Grade 1-2 thrombopaenia occurred in 3 (9%) patients, grade >2 leukopaenia in 4(11%) patients. and grade greater than or equal to2 anaemia in 3 (9%) patients. We observed a treatment interruption of maximum 1 week for six patients owing to mucositis. Febrile neutropaenia or aplasia were not observed. The concomitant use of 5-fluorouracil, mitomycin-C and radiotherapy in locally advanced head and neck carcinoma is well tolerated in this group of patients. This protocol showed good locoregional response with a very low toxicity profile
Jean-Marie Pradier : La Scène et la Fabrique des corps. Ethnoscénologie du spectacle (5e siècle av. J.-C.-18e siècle), 2000
No full textL'Aminot Tanguy. Jean-Marie Pradier : La Scène et la Fabrique des corps. Ethnoscénologie du spectacle (5e siècle av. J.-C.-18e siècle), 2000. In: Dix-huitième Siècle, n°33, 2001. L'Atlantique, sous la direction de Marcel Dorigny . pp. 706-707
In regards to: Adjuvant radiotherapy after transoral laser microsurgery for advanced squamous cell carcinoma of the head and neck by Pradier et al. (Int J Radiat Oncol Biol Phys 2005;63 : 1368-1377) - In reply to Drs. Cengiz Et Al.
No full textGoing Beyond Counting First Authors in Author Co-citation Analysis
No full textThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
L'âne de Suzanne : historiette / paroles de C. Pradier ; musique de Paul Blaquière
No full textChansons françaises -- +* 1800......- 1899......+:19e siècle
Concomitant radiochemotherapy in primary inoperable advanced head and neck cancer with 5-fluorouracil and mitomycin-C
No full textBackground. The purpose of this study was to evaluate the efficacy and toxicity of radiotherapy and concomitant 5-fluorouracil (5-FU) and mitomycin-C infusion in inoperable head and neck cancer. Methods. Seventy-six patients (86% men, 14% women), mean age 57 years, with primary inoperable head and neck cancer were treated with 70 Gy plus simultaneous intravenous chemotherapy with 5-FU (600 mg/m(2)/d, days 1 to 5) and mitomycin-C (10 mg/m(2), day 5 plus 36). Results. After a mean follow-up of 13 months, 31 patients were alive. Complete response (CR) was seen in 63%. The 1- and 2-year overall survival rates were 67.7% and 39.5%, and locoregional control rates were 51.7% and 35.6%. Pretreatment hemoglobin <13.9 g/dL was associated with lower locoregional control rates (p = .03). Therapy was well tolerated (grade 3 mucositis in 21%, grade 4 in 1%, grade 3 leukopenia in 11%). Conclusions. Our radiochemotherapy regimen offers a curative option for this group of patients with a poor prognosis. Hemoglobin levels before therapy have an influence on prognosis. (C) 2004 Wiley Periodicals, Inc
Interindividual variations in positioning accuracy and patient motion during pelvic radiotherapy
No full textAdjuvant radiotherapy after transoral microlasersurgery for advanced primary squamous cell carcinoma of the head and neck
No full text- …
